Literature DB >> 19858253

Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.

N Patel1, M H Scheetz, G L Drusano, T P Lodise.   

Abstract

This study examined the effect of various levels of renal impairment on the probability of achieving free drug concentrations that exceed the MIC for 50% of the dosing interval (50% fT > MIC) for traditional and extended-infusion piperacillin-tazobactam (TZP) dosing strategies. It also identified optimal renal dosage adjustments for traditional and extended-infusion dosing schemes that yielded probability of target attainment (PTA) and exposure profiles that were isometric to those of the parent regimens. Data from 105 patients were analyzed using the population pharmacokinetic modeling program BigNPAG. To assess the effect of creatinine clearance (CL(CR)) on overall clearance, TZP clearance was made proportional to the estimated CL(CR). A Monte Carlo simulation (9,999 subjects) was performed for the traditional dosing scheme (4.5 g infused during 30 min every 6 h) and the extended-infusion TZP dosing scheme (3.375 g infused during 4 h every 8 h). The fraction of simulated subjects who achieved 50% fT > MIC was calculated for the range of piperacillin MICs from 0.25 to 32 mg/liter and stratified by CL(CR). The traditional TZP regimen displayed the greatest variability in PTA across MIC values, especially for MIC values exceeding 4 mg/liter, when stratified by CL(CR). In contrast, the PTA for the extended-infusion TZP regimen exceeded >or=80% for MIC values of <or=8 mg/liter across all CL(CR) strata. All regimens were associated with suboptimal PTA for MIC values of >or=32 mg/liter irrespective of the CL(CR). The CL(CR) adjustments for traditional and extended-infusion TZP dosing regimens should be considered at a CL(CR) of <or=20 ml/min.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858253      PMCID: PMC2798531          DOI: 10.1128/AAC.00296-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.

Authors:  M Kinzig; F Sörgel; B Brismar; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 2.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Authors:  George L Drusano
Journal:  Nat Rev Microbiol       Date:  2004-04       Impact factor: 60.633

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Bacteriostatic and bactericidal activities of selected beta-lactam antibiotics studied on agar plates.

Authors:  G Masuda; S Tomioka; H Uchida; M Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

5.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

Review 6.  Pharmacokinetics of the penicillins in man.

Authors:  M Barza; L Weinstein
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.

Authors:  Joseph L Kuti; Charles H Nightingale; Richard Quintiliani; David P Nicolau
Journal:  Diagn Microbiol Infect Dis       Date:  2002-09       Impact factor: 2.803

8.  Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.

Authors:  Myo-Kyoung Kim; Blair Capitano; Holly M Mattoes; Dawei Xuan; Richard Quintiliani; Charles H Nightingale; David P Nicolau
Journal:  Pharmacotherapy       Date:  2002-05       Impact factor: 4.705

9.  Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time.

Authors:  H Hanberger
Journal:  Scand J Infect Dis Suppl       Date:  1992

10.  The effect of piperacillin dose on elimination kinetics in renal impairment.

Authors:  G R Aronoff; R S Sloan; M E Brier; F C Luft
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more
  15 in total

1.  Importance of infusion volume and pump characteristics in extended administration of ß-lactam antibiotics.

Authors:  Barbara Claus; Franky Buyle; Hugo Robays; Dirk Vogelaers
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

Review 2.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

3.  Suboptimal antimicrobial drug exposure in patients with renal impairment.

Authors:  David Czock; Martino Spitaletta; Frieder Keller
Journal:  Int J Clin Pharm       Date:  2015-05-28

4.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

5.  Mitochondrial GTP Links Nutrient Sensing to β Cell Health, Mitochondrial Morphology, and Insulin Secretion Independent of OxPhos.

Authors:  Sean R Jesinkey; Anila K Madiraju; Tiago C Alves; OrLando H Yarborough; Rebecca L Cardone; Xiaojian Zhao; Yassmin Parsaei; Ali R Nasiri; Gina Butrico; Xinran Liu; Anthony J Molina; Austin M Rountree; Adam S Neal; Dane M Wolf; John Sterpka; William M Philbrick; Ian R Sweet; Orian H Shirihai; Richard G Kibbey
Journal:  Cell Rep       Date:  2019-07-16       Impact factor: 9.423

6.  Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.

Authors:  T P Lodise; J M Butterfield; S S Hegde; E Samara; S L Barriere
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

7.  Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.

Authors:  Elias Tannous; Shelly Lipman; Antonella Tonna; Emma Hector; Ziad Hussein; Michal Stein; Sharon Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

8.  Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?

Authors:  Andrew A Udy; Jeffrey Lipman; Paul Jarrett; Kerenaftali Klein; Steven C Wallis; Kashyap Patel; Carl M J Kirkpatrick; Peter S Kruger; David L Paterson; Michael S Roberts; Jason A Roberts
Journal:  Crit Care       Date:  2015-01-30       Impact factor: 9.097

9.  Pulmonary penetration of piperacillin and tazobactam in critically ill patients.

Authors:  T W Felton; K McCalman; I Malagon; B Isalska; S Whalley; J Goodwin; A M Bentley; W W Hope
Journal:  Clin Pharmacol Ther       Date:  2014-06-13       Impact factor: 6.875

10.  Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.

Authors:  T W Felton; J A Roberts; T P Lodise; M Van Guilder; E Boselli; M N Neely; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.